Clostridium difficile infection following hip fracture.
Fenton
P
P
Singh
K
K
Cooper
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000009:adverse effects*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D015897:Comorbidity; D003428:Cross Infection / Q000139:chemically induced / Q000453:epidemiology* / Q000382:microbiology; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced / Q000453:epidemiology* / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005260:Female; D006620:Hip Fractures / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D006113:United Kingdom / Q000453:epidemiology
D000900:Anti-Bacterial Agents